Led · Series A · Jul 2026

TYBR Health develops extracellular matrix-based products intended to protect healing tissues following surgery, centered on its FDA-cleared B3 GEL® System. B3 GEL® is a flowable extracellular matrix hydrogel designed to conform to complex three-dimensional anatomy and be rapidly applied within existing surgical workflows. Since launch, the system has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures, with early adoption by surgeons seeking straightforward intraoperative tissue protection. The company says the product adheres where applied and forms a protective barrier through the healing window. TYBR Health plans to use the Series A proceeds to expand commercial access, broaden indications, and run clinical studies evaluating tissue protection during orthopedic surgery. The company is headquartered in Houston, Texas.

Participated · Series B · Jan 2026

Apella Technology has built an "ambient video intelligence" layer for procedural environments, beginning with the operating room. Its platform uses computer vision and machine learning to automatically detect and label up to 14 surgical case events and then write that data directly into the electronic health record, cutting manual documentation and improving situational awareness. Hospitals deploying Apella report an average 5 % rise in surgical volume as better coordination unlocks capacity and reduces delays. Houston Methodist, a nine-hospital system, expanded from a 36-room pilot to more than 200 operating rooms, illustrating enterprise-scale adoption. The company has also extended its technology to interventional radiology, cardiology and endoscopy suites for broader operational visibility. A new module, Horizon, delivers more accurate case-duration estimates and utilization predictions to optimize scheduling before each day begins. Apella positions itself within the growing "ambient AI" trend in healthcare and was named to Fast Company’s 2025 Most Innovative Companies list.

Participated · Series A · Jan 2026

Ventaris Surgical is a privately held med-tech firm focused on improving kidney stone surgery through a novel ureteroscopic system that minimizes friction in the procedure and helps surgeons attain consistent, complete stone clearance. The company asserts that current instruments make it difficult to reliably remove all stones because of anatomical variation, stone burden, workflow constraints, and surgeon fatigue. By redesigning the toolset, Ventaris intends to boost surgical outcomes while easing surgeon workload. Headquartered in San Carlos, California, the startup is still in the clinical development stage and has not disclosed commercial revenues or user metrics. It plans to use newly raised capital to advance clinical studies and achieve key regulatory and commercial milestones. Board expansion accompanies the financing, adding Varun Gupta (Longitude Capital) and Justin Klein (Vensana Capital) alongside independent director Amir Abolfathi.

Participated · Equity · Nov 2025

Okami Medical is a privately held medical technology company focused on creating versatile, intuitive devices for peripheral vascular occlusion. Founded in 2017 by Inceptus Medical and headquartered in Aliso Viejo, California, the company’s flagship product is the LOBO vascular occluder, which has demonstrated clinical performance across a wide range of anatomies. Okami’s mission is to stop blood flow where needed and thereby restore patients’ lives, addressing significant unmet needs in vascular disease treatment. With its latest capital infusion, the company plans to accelerate commercial expansion, advance ongoing clinical programs, and fuel continued product innovation. The leadership team was recently strengthened by the appointment of former Inari Medical CEO Drew Hykes as President and CEO, and Bill Hoffman as Chairman of the Board. Okami positions itself at the intersection of med-tech innovation and improved patient care, leveraging a growing base of investor support to scale its technology.

Led · Series A · Aug 2025

Luna Diabetes develops a method of insulin delivery for insulin pen users; its flagship product, Luna, pairs a small insulin patch pump with a closed-loop algorithm to automate insulin delivery during sleep and support users across the day. The product is designed to provide automation without requiring a switch to a full-time insulin pump. The company is based in San Diego, CA. Luna raised $23.6M in a Series A financing. It intends to use the funds to advance regulatory submissions, conduct clinical studies, build manufacturing capacity, and expand clinical and market access programs.